Amyloid imaging with [18F]florbetapir in geriatric depression: Early-onset versus late-onset

International Journal of Geriatric Psychiatry

Volumn 30, Issue 7, 2015, Pages 720-728

  Tateno, Amane ^a   Sakayori, Takeshi ^a   Higuchi, Makoto ^b   Suhara, Tetsuya ^b   Ishihara, Keiichi ^a   Kumita, Shinichiro ^a   Suzuki, Hidenori ^a   Okubo, Yoshiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Alzheimer's disease; beta amyloid; geriatric depression; positron emission tomography

Indexed keywords

AMITRIPTYLINE; AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; DONEPEZIL; DULOXETINE; ESCITALOPRAM; FLORBETAPIR F 18; FLUVOXAMINE; LEVOTHYROXINE SODIUM; LITHIUM CARBONATE; MEMANTINE; MIANSERIN; MIRTAZAPINE; NOOTROPIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG; VALPROIC ACID; YOKUKANSAN; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR;

AGED; ARTICLE; BRAIN ATROPHY; CLINICAL DEMENTIA RATING SCALE; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GERIATRIC DEPRESSION; GERIATRIC DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; RATING SCALE; AMYLOID PLAQUE; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATHOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SCINTISCANNING; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; ETHYLENE GLYCOLS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES;

EID: 84930720269     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4215     Document Type: Article

References (34)

1. Belanoff JK, Gross K, Yager A, Schatzberg AF,. 2001. Corticosteroids and cognition. J Psychiatr Res 35: 127-145.
2. Borroni B, Archetti S, Costanzi C, et al,. 2009. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol Aging 30: 1406-1412.
3. Butters MA, Klunk WE, Mathis CA, et al,. 2008. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord 22: 261-268.
4. Byers AL, Yaffe K,. 2011. Depression and risk of developing dementia. Nat Rev Neurol 7: 323-331.
5. Camus V, Payoux P, Barre L, et al,. 2012. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging 39: 621-631.
6. Caraci F, Copani A, Nicoletti F, Drago F,. 2010. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. Eur J Pharmacol 626: 64-71.
7. Chen KH, Reese EA, Kim HW, Rapoport SI, Rao JS,. 2011. Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J Alzheimer Dis 26: 755-766.
8. Doraiswamy PM, Sperling RA, Coleman RE, et al,. 2012. Amyloid-beta assessed by Florbetapir F 18 PET and 18-months cognitive decline. Neurology 79: 1636-1644.
9. Elobeid A, Soininen H, Alafuzoff I,. 2012. Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol 123: 97-104.
10. Fazekas F, Kleinert R, Offenbacher H, et al,. 1991. The morphologic correlate of incidental punctate white matter hyperintensities on MR images. AJNR Am J Neuroradiol 12: 915-921.
11. Fleisher AS, Chen K, Liu X,. 2011. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 68: 1404-1411.
12. Folstein MF, Folstein SE, McHugh PR,. 1975. " Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
13. Geerlings MI, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM,. 2008. History of depression, depressive symptoms, and medical temporal lobe atrophy and the risk of Alzheimer disease. Neurology 70: 1258-1264.
14. Hirata Y, Matsuda H, Nemoto K, et al,. 2005. Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 382: 269-274.
15. Hochstrasser T, Hohsfield LA, Sperner-Unterweger B, Humpel C,. 2013. β-Amyloid induced effects on cholinergic, serotonergic, and dopaminergic neurons is differentially counteracted by anti-inflammatory drugs. J Neurosci Res 91: 83-94.
16. Jack CR Jr, Lowe VJ, Weigand SD, et al,. 2009. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological event in Alzheimer's disease. Brain 132: 1355-1365.
17. Johnson KA, Sperling RA, Gidicsin CM, et al,. 2013. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 9: S72-S83.
18. Kramberger MG, Jelic V, Kåreholt I, et al,. 2012. Cerebrospinal fluid Alzheimer markers in depressed elderly subjects with and without Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2: 48-56.
19. Kumar A, Kepe V, Barrio JR, et al,. 2011. Protein binding in patients with late-life depression. Arch Gen Psychiatry 68: 1143-1150.
20. Ledo JH, Azevedo EP, Clarke JR, et al,. 2012. Amyloid-beta oligomers link depressive-like behavior and cognitive deficits in mice. Mol Psychiatry 18: 1053-1054.
21. Madsen K, Hasselbalch BJ, Frederiksen KS, et al,. 2008. Lack of association between prior depressive episodes and cerebral [11C]PiB binding. Neurobiol Aging 33: 2334-2342.
22. Morris JC,. 1993. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
23. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D,. 2006. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63: 530-538.
24. Petersen RC, Morris JC,. 2005. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62: 1160-1163.
25. Pomara N, Bruno D, Sarreal AS, et al,. 2012. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 169: 523-530.
26. Rapp MA, Schnaider-Beeri M, Purohit DP, et al,. 2008. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry 16: 168-174.
27. Sheikh JI, Yesavage JA,. 1986. Geriatric Depression Scale (GDS) Recent evidence and development of a shorter version. In Clinical Gerontology: A Guide to Assessment and Intervention, Brink TL, (ed.). The Haworth Press: New York; 165-173.
28. Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J,. 2010. Major depression, cognitive dysfunction and Alzheimer's disease: is there a link? Eur J Pharmacol 626: 72-82.
29. Starkstein SE, Dragovic M, Jorge R, Brockman S, Robinson RG,. 2011. Diagnostic criteria for depression in Alzheimer disease: a study of symptom patterns using latent class analysis. Am J Geriatr Psychiatry 19: 551-558.
30. Sun X, Steffens DC, Au R, et al,. 2008. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 65: 542-550.
31. Tateno A, Sakayori T, Kawashima Y, et al,. 2014. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with florbetapir F18 positron emission tomography and MRI voxel-based analysis for entorhinal cortex atrophy. Int J Geriatr Psychiatry. DOI: 10.1002/gps.4173 [Epub ahead of print].
32. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al,. 2002. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15: 273-289.
33. Wu KY, Hsiao IT, Chen CS, et al,. 2014. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography. Eur J Nucl Med Mol Imaging 41: 714-722.
34. Zarow C, Lyness SA, Mortimer JA, Chui HC,. 2003. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60: 337-341.